Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Candoni, Anna  [Clear All Filters]
2015
Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jiménez JLópez, Candoni A, Raad I, Laverdiere M, Langston A, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2015.
2018
Cojutti PGiorgio, Candoni A, Lazzarotto D, Rabassi N, Fanin R, Hope W, Pea F. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies. Br J Clin Pharmacol. 2018.
Falconi G, Fabiani E, Piciocchi A, Criscuolo M, Fianchi L, Rossi ELLindfors, Finelli C, Cerqui E, Ottone T, Molteni A, et al. Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Leukemia. 2018.
2019
Trecarichi EMaria, Giuliano G, Cattaneo C, Ballanti S, Criscuolo M, Candoni A, Marchesi F, Laurino M, Dargenio M, Fanci R, et al. Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. PLoS One. 2019;14(10):e0224465.
Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, et al. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Societ. Biol Blood Marrow Transplant. 2019.
2020
Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, Del Principe MIlaria, Bonifacio M, Mosna F, Delia M, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma. the campus-all study. Am J Hematol. 2020.
2021
Facchin G, Candoni A, Lazzarotto D, Zannier MElena, Peghin M, Sozio E, Pellegrini N, Filì C, Sartor A, Tascini C, et al. Clinical characteristics and outcome of 125 polymicrobial bloodstream infections in hematological patients: an 11-year epidemiologic survey. Support Care Cancer. 2021.
Buccisano F, Palmieri R, Piciocchi A, Arena V, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, et al. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. Blood Adv. 2021.
Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, Marconi G, Lemoli RMassimo, Guolo F, Fornaro A, et al. INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv. 2021.
Del Principe MIlaria, Dragonetti G, Conti A, Verga L, Ballanti S, Fanci R, Candoni A, Marchesi F, Cattaneo C, Lessi F, et al. Invasive aspergillosis in relapsed/refractory acute myeloid leukemia patients. Results from SEIFEM 2016-B survey. Mycoses. 2021.
Sperotto A, Gottardi M, Candoni A, Toffoletti E, De Marchi R, Petruzzellis G, Pizzano U, Fanin R. WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant. Leuk Res. 2021;108:106587.
2022
Marasco V, Piciocchi A, Candoni A, Pagano L, Guidetti A, Musto P, Bruna R, Bocchia M, Visentin A, Turrini M, et al. Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study. Br J Haematol. 2022.
2023
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, et al. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2023;10(11):e879-e889.
Trecarichi EMaria, Giuliano G, Cattaneo C, Ballanti S, Criscuolo M, Candoni A, Marchesi F, Laurino M, Dargenio M, Fanci R, et al. Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey. Int J Antimicrob Agents. 2023:106806.
Gilioli A, Bresciani P, Franceschini E, Messerotti A, Pioli V, Colasante C, Bettelli F, Giusti D, Forghieri F, Morselli M, et al. COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit. Int J Hematol. 2023.
Bassan R, Chiaretti S, Starza IDella, Spinelli O, Santoro A, Paoloni FPaola, Messina M, Elia L, De Propris MStefania S, Scattolin AMaria, et al. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023.
Menna P, Marchesi F, Cattaneo C, Candoni A, Delia M, Nadali G, Vatteroni A, Pasciolla C, Perrone S, Verga L, et al. Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study. Clin Transl Sci. 2023.
De Cicco M, Lagreca I, Basso S, Barozzi P, Muscianisi S, Bianco A, Riva G, Di Vincenzo S, Pulvirenti C, Sapuppo D, et al. Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1) for the Treatment of NPM1-Acute Myeloid Leukemia. Cancers (Basel). 2023;15(10).
Callegari C, Lazzarotto D, Soravia A, Mutti M, Lauzzana P, Peghin M, Cordella S, Fanin R, Candoni A. Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination. Eur J Haematol. 2023.